Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

(MedPage Today) -- The investigational bispecific antibody ivonescimab significantly improved overall survival (OS) in PD-L1-positive advanced non-small cell lung cancer (NSCLC) compared with single-agent pembrolizumab (Keytruda), an updated analysis...